GeneTether Therapeutics (CSE: GTTX) is focused on developing its disruptive proprietary platform technology to significantly increase the efficiency of DNA insertion into the genome for gene correction and complementation strategies. GeneTether’s wholly-owned platform technology uses a proprietary method to “tether” donor DNA templates to the genome editing complex, making the template readily available for use during the genome editing repair stage.
Company Details
- Founded
- -
- Address
- Toronto, Ca
- Industry
- Biotechnology
- Website
- https://genetether.com
- HQ
- Toronto
Genetether Therapeutics Inc (Cse: Gttx) Questions
Genetether Therapeutics Inc (Cse: Gttx)'s website is https://genetether.com
Genetether Therapeutics Inc (Cse: Gttx)'s LinkedIn profile is https://www.linkedin.com/company/genetether-inc
Genetether Therapeutics Inc (Cse: Gttx)'s industry is
Biotechnology
Genetether Therapeutics Inc (Cse: Gttx)'s top competitors are
Muwells, Inc.,
Pinnacle Oncology,
Shackelford Pharma Inc,
Rize Oncology,
Gb Ventures,
Ninevah Therapeutics,
Mclean Canadian Consulting,
Fp&a Navigator,
Bioscience Oncology,
Vivia Oncology.
Genetether Therapeutics Inc (Cse: Gttx)'s categories are Biotechnology
Genetether Therapeutics Inc (Cse: Gttx)'s founding year is 2018
